FRUIT OF THE LOOM® and RECOVER™ Launch Affordable and Sustainable T-shirt Collection
14.9.2022 18:05:00 EEST | Business Wire | Press release
Fruit of the Loom, maker of the iconic FRUIT OF THE LOOM® branded apparel, is partnering with leading materials science company, Recover Textile Systems, S.L., maker of Recover™ fiber, to release a new collection of classic, unisex t-shirts beginning today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005104/en/
Fruit of the Loom® has partnered with Recover™ to release a collection of classic, unisex t-shirts made from responsibly sourced fabric and material. (Photo: Recover™)
With inclusive sizing and responsibly sourced fabric and material, each sustainably designed t-shirt is made with 20% Recover™ best-in-class recycled cotton fiber and is available in eight colors. Each t-shirt is priced at $15. The limited-edition collection will be available for purchase starting August 30 on Fruit.com and Amazon, while supplies last.
The new Recover™ cotton t-shirt collection is one of the many ways Fruit of the Loom is delivering against their goal to “increase sustainable sourcing across key materials” as outlined in the company’s global sustainability plan, Fruitful Futures™. The plan documents specific commitments across three key pillars—People-Centric, Planet-Conscious and Product Authenticity.
“This collection is the latest way Fruit of the Loom is producing more sustainable products across the entire business. As one of the world’s largest manufacturers and marketers of casual wear, we are committed to reducing our environmental impact across the total value chain,” said Mercedes Lopez, Vice President of Corporate Social Responsibility at Fruit of the Loom.
The partnership with Recover and the use of their cotton enables the company to offer a circular sustainable program that utilizes textile production waste to create high-quality recycled cotton fiber. Recover’s proprietary recycled cotton fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel produced with the fiber. By partnering with Recover, Fruit of the Loom continues to demonstrate its innovation and commitment to sustainability.
"We're delighted to collaborate with Fruit of the Loom in order to accelerate the adoption of sustainable initiatives within the casual wear segment. The universality of the collection perfectly fits with the values of the Recover™ brand to achieve circular fashion for all,” said Boris Mercier, Senior Vice President of Marketing at Recover.
For more information on the new collection or Fruit of the Loom’s sustainability commitments, visit Fruit.com.
About Recover
Recover is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets. For more information, visit www.recoverfiber.com and follow @recoverfiber on social media.
About Fruit of the Loom
For 170 years, Fruit of the Loom has been a trusted expert in underwear and casual apparel, crafting comfortable, quality products for everybody and every body. We obsess over even the smallest details so people can feel free to focus on the things that matter most to them. And we try not to take ourselves too seriously – it's just more fun that way. For more information about Fruit of the Loom, visit us at Fruit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005104/en/
Contact information
Media Contact
fruitcoreteam@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom